Our Studies/ Scientific Programs

Canine Lymphoma Clinical Trial Study Goals: The Stratification of Outcomes for Lymphoma In Dogs (SOLID) study is a clinical trial focused on better understanding the genetics behind canine lymphoma. By studying changes in the DNA of these cancers, researchers hope to identify patterns that could lead to more personalized treatment options. The goal is to find markers

FICUSS Study Study Goals: FICUSS Study looks to improve understanding of Feline Idiopathic Cystitis. The collected samples will be used to help better understand the underlying pathophysiology of this disease, which can then be used to aid in the development of novel diagnostic tests and targeted therapies for this condition. Eligibility criteria: Male cats greater

Currently Enrolling Comparison of diet alone vs. diet and probiotic to control clinical signs of chronic enteropathy in dogs Study Goals: This study aims to address the unmet of chronic enteropathy and, in particular, chronic diarrhea in dogs. Treatments for this condition are often empirical and nonspecific. Recently, altering the gut microbiota in patients with

CURRENTLY ENROLLING The MIMIC clinical trial is open for enrollment. Ethos Discovery is investigating a new minimally-invasive surgical treatment for canine osteosarcoma that has metastasized, or spread, to the lungs. This study is subsidized and all procedures will be provided at an affordable, low cost. Eligibility Criteria: • Dogs weighing >5 kgs with a diagnosis

We are collecting blood samples from eligible French Bulldogs to research biomarkers associated with hemorrhages (bleeding) in French bulldogs.

Ethos Discovery seeks to investigate a new approach to reducing hemorrhages (bleeding) in French Bulldogs following slipped discs in their back.

Current chemotherapy treatments involve a direct injection into the tumor. We would like to use surgically removed lung tissue to better understand how drugs behave when they are injected into lung tumors in dogs, as well as humans, with lung tumors.

Postoperative regurgitation is a common side effect of general anesthesia; it is of clinical concern due to the increased risk of pneumonia. This study seeks to define the rate at which intravenously administered MNTX in healthy dogs is metabolized. Once defined, a future study will evaluate the efficacy of this treatment in reducing postoperative regurgitation in dogs.

Necrotizing Meningoencephalitis in Pugs (PDE) is a devastating disease. Clinical signs include seizures, circling, cognitive changes, and visual deficits. Our goal is to identify neurological abnormalities in Pugs with high genomic risk for PDE before the onset of the above-mentioned advanced clinical signs.

We are studying a novel live probiotic product typically found in the gut of healthy dogs to evaluate the ability of this probiotic to resolve diarrhea in dogs.

Proliferating cell nuclear antigen (PCNA) is an important protein necessary for the repair of DNA in cells. Cancer cells express a unique type of PCNA (termed caPCNA) which is only found at small quantities in non-cancer cells.

Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.